Last update 09 Jun 2026

BL-M08D1

Overview

Basic Info

Drug Type
Antibody drug conjugate (ADC)
Synonyms
BL M08D1, BLM08D1
Target
Trop-2
Action
modulators
Mechanism
Trop-2 modulators(Tumor-associated calcium signal transducer 2 modulators)
Therapeutic Areas
NeoplasmsImmune System DiseasesHemic and Lymphatic Diseases
Active Indication
Locally Advanced Malignant Solid NeoplasmLymphomaDiffuse Large B-Cell Lymphoma+ [2]
Inactive Indication-
Originator Organization
Sichuan Biokin Pharmaceutical Co., Ltd.Sichuan Biokin Pharmaceutical Co., Ltd.
Active Organization
Sichuan Baili Pharmaceuticals Co.,LtdSichuan Baili Pharmaceuticals Co.,LtdSichuan Biokin Pharmaceutical Co., Ltd.Sichuan Biokin Pharmaceutical Co., Ltd.
Inactive Organization-
License Organization-
Drug Highest PhasePhase 1
First Approval Date-
Regulation-
Login to view timeline

Structure/Sequence

Boost your research with our ADC technology data.
login
or
view full example data
Boost your research with our ADC technology data.

Related

3
Clinical Trials associated with BL-M08D1
NCT06718621
/ RecruitingPhase 1
A Phase I Study to Evaluate the Safety, Tolerability, Pharmacokinetic Characteristics and Preliminary Efficacy of BL-M08D1 for Injection in Patients With Locally Advanced or Metastatic Solid Tumors
NCT06718634
/ RecruitingPhase 1
A Phase I Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetic Characteristics and Preliminary Efficacy of BL-M08D1 for Injection in Patients With Relapsed or Refractory Lymphoid Malignancies
ChiCTR2500108689
/ RecruitingPhase 1
A Phase I Study to Evaluate the Safety, Tolerability, Pharmacokinetic Characteristics and Preliminary Efficacy of BL-M08D1 for Injection in Patients With Locally Advanced or Metastatic Solid Tumors
100 Clinical Results associated with BL-M08D1
Login to view more data
100 Translational Medicine associated with BL-M08D1
Login to view more data
100 Patents (Medical) associated with BL-M08D1
Login to view more data
100 Deals associated with BL-M08D1
Login to view more data

R&D Status

10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Locally Advanced Malignant Solid NeoplasmPhase 1
China
Sichuan Baili Pharmaceuticals Co.,LtdSichuan Baili Pharmaceuticals Co.,Ltd
12 Feb 2025
LymphomaPhase 1
China
Sichuan Baili Pharmaceuticals Co.,LtdSichuan Baili Pharmaceuticals Co.,Ltd
02 Jan 2025
Diffuse Large B-Cell LymphomaIND Approval
China
Sichuan Baili Pharmaceuticals Co.,LtdSichuan Baili Pharmaceuticals Co.,Ltd
01 Jun 2026
Hematologic NeoplasmsIND Approval
China
Sichuan Biokin Pharmaceutical Co., Ltd.Sichuan Biokin Pharmaceutical Co., Ltd.
25 Nov 2024
Metastatic Solid TumorIND Approval
China
Sichuan Biokin Pharmaceutical Co., Ltd.Sichuan Biokin Pharmaceutical Co., Ltd.
25 Nov 2024
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date

No Data

Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
login
or
view full example data
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
login
or
view full example data
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
login
or
view full example data
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
login
or
view full example data
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
login
or
view full example data
Accelerate your research with the latest regulatory approval information.

Biosimilar

Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.
login
or
view full example data
Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.

Regulation

Understand key drug designations in just a few clicks with Synapse.
login
or
view full example data
Understand key drug designations in just a few clicks with Synapse.
AI Agents Built for Biopharma Breakthroughs
Accelerate discovery. Empower decisions. Transform outcomes.
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free